User menu

Dopamine D-3 agonists

Bibliographic reference Emilien, G ; Durlach, C ; Aveaux, D ; Maloteaux, Jean-Marie. Dopamine D-3 agonists. In: Expert Opinion on Therapeutic Patents, Vol. 11, no. 11, p. 1713-1728 (2001)
Permanent URL
  1. Sokoloff Pierre, Giros Bruno, Martres Marie-Pascale, Bouthenet Marie-Louise, Schwartz Jean-Charles, Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics, 10.1038/347146a0
  2. Zaborszky Laszlo, Vadasz Csaba, 10.1023/a:1010257808945
  3. Hantraye Philippe, Modeling dopamine system dysfunction in experimental animals, 10.1016/s0969-8051(98)00054-7
  4. Skoog B., Noga B.R., Dopaminergic control of transmission from group II muscle afferents to spinal neurones in the cat and guinea-pig, 10.1007/bf00242180
  5. UN SC, Mayo. Gbh. Proc., 73, 497 (1998)
  6. Qing-Song Liu, Jian-Tian Qiao, Dafny Nachum, D2 dopamine receptor involvement in spinal dopamine-produced antinociception, 10.1016/0024-3205(92)90558-7
  7. Cox Barbara A., Rosser Mary P., Kozlowski Michal R., Duwe Kevin M., Neve Rachael L., Neve Kim A., Regulation and functional characterization of a rat recombinant dopamine D3 receptor, 10.1002/syn.890210102
  8. Bouthenet Marie-Louise, Souil Evelyne, Martres Marie-Pascale, Sokoloff Pierre, Giros Bruno, Schwartz Jean-Charles, Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA, 10.1016/0006-8993(91)91456-b
  9. Levesque D., Diaz J., Pilon C., Martres M. P., Giros B., Souil E., Schott D., Morgat J. L., Schwartz J. C., Sokoloff P., Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin., 10.1073/pnas.89.17.8155
  10. Daly Siobhan A., Waddington John L., Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other “D-2-like” agonists, 10.1016/0028-3908(93)90177-5
  11. Svensson K., Carlsson A., Waters N., Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release, 10.1007/bf01283032
  12. Accili D., Fishburn C. S., Drago J., Steiner H., Lachowicz J. E., Park B. H., Gauda E. B., Lee E. J., Cool M. H., Sibley D. R., Gerfen C. R., Westphal H., Fuchs S., A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice., 10.1073/pnas.93.5.1945
  13. Menalled Liliana B., Dziewczapolski Gustavo, Garcia Maria C., Rubinstein Marcelo, Gershanik Oscar S., D3 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion : , 10.1097/00001756-199910190-00002
  14. Lundstrom Kenneth, Turpin Michael P., Proposed Schizophrenia-Related Gene Polymorphism: Expression of the Ser9Gly Mutant Human Dopamine D3Receptor with the Semliki Forest Virus System, 10.1006/bbrc.1996.1296
  15. Landwehrmeyer B., Mengod G., Palacios J.M., Dopamine D3 receptor mRNA and binding sites in human brain, 10.1016/0169-328x(93)90188-u
  16. LEVANT B, Phannacol. Rev, 49, 231 (1997)
  17. Schmauss C., Haroutunian V., Davis K. L., Davidson M., Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia., 10.1073/pnas.90.19.8942
  18. CAINE SB, Science, 1993, 1814
  19. STALEY JK, Neurosci, 16, 6100 (1996)
  20. CUMMINGS JL, I Neural. Sri., 163, 2 (1999)
  21. SZEGEDI A, Glitz Neurapharmacal., 20, S36–S45 (1997)
  22. Knight Darryl A., Stewart Geoffrey A., Thompson Philip J., Prostaglandin E2, but not prostacyclin inhibits histamine-induced contraction of human bronchial smooth muscle, 10.1016/0014-2999(94)00602-4
  23. GRIFFON N, Biachein. Soc. Transit., 24, 193 (1996)
  24. PUGSLEY TA, Pharinacal. Exp. Ther., 275, 1355 (1995)
  25. Steiner Heinz, Fuchs Sara, Accili Domenico, D3 Dopamine Receptor-Deficient Mouse: Evidence for Reduced Anxiety, 10.1016/s0031-9384(97)00430-7
  26. Gilbert David B., Millar Julian, Cooper Steven J., The putative dopamine D3 agonist, 7-OH-DPAT, reduces dopamine release in the nucleus accumbens and electrical self-stimulation to the ventral tegmentum, 10.1016/0006-8993(95)00247-n
  27. Smith A.G, Neill J.C, Costall B, The Dopamine D3/D2 Receptor Agonist 7-OH-DPAT Induces Cognitive Impairment in the Marmoset, 10.1016/s0091-3057(98)00230-5
  28. Guttman M., Jaskolka J., The use of pramipexole in Parkinson's disease: are its actions D3 mediated?, 10.1016/s1353-8020(00)00062-6
  29. Lagos Patricia, Scorza Cecilia, Monti Jaime M, Jantos Héctor, Reyes-Parada Miguel, Silveira Rodolfo, Ponzoni Ana, Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats, 10.1016/s0924-977x(97)00054-0
  30. CHU E, j Pharmacy]. Exp. Ther., 293, 710 (2000)
  31. Fink-Jensen Anders, Nielsen Erik Bardrum, Hansen Liselotte, Scheideler Mark A, Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI, 10.1016/s0014-2999(97)01494-5
  32. Ikonen Sami, Schmidt Bernard, Riekkinen Paavo, Apamin improves spatial navigation in medial septal-lesioned mice, 10.1016/s0014-2999(98)00075-2
  33. Wustrow David, Belliotti Thomas, Glase Shelly, Kesten Suzanne Ross, Johnson Don, Colbry Norman, Rubin Ronald, Blackburn Anthony, Akunne Hyacinth, Corbin Ann, Davis M. Duff, Georgic Lynn, Whetzel Steven, Zoski Kim, Heffner Thomas, Pugsley Thomas, Wise Lawrence, Aminopyrimidines with High Affinity for Both Serotonin and Dopamine Receptors, 10.1021/jm9707378
  34. HORNYKIEWICZ, Neurology, 51, S2–S9 (1998)
  35. Ryoo Han L., Pierrotti Dylan, Joyce Jeffrey N., Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease, 10.1002/mds.870130506
  36. Joyce J.N., Ryoo H., Gurevich E.V., Adler C., Beach T., Ventral striatal D3 receptors and Parkinson's Disease, 10.1016/s1353-8020(00)00060-2
  37. Perachon Sylvie, Schwartz Jean-Charles, Sokoloff Pierre, Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors, 10.1016/s0014-2999(98)00896-6
  38. Svensson Kjell, Carlsson Arvid, Huff Rita M., Kling-Petersen Torben, Waters Nicholas, Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors, 10.1016/0014-2999(94)90718-8
  39. Carvey P.M., McGuire S.O., Ling Z.D., Neuroprotective effects of D3 dopamine receptor agonists, 10.1016/s1353-8020(00)00061-4
  40. KITAMURA Y, Mal Pharmacy], 54, 1046 (1998)
  41. GITTELMAN R, I. Psychiatric status. Arch. Len. Psychiatry, 42, 937 (1985)
  42. Levy Florence, Ban Cathy, Sunohara Glen, Directions of Aetiologic Research on Attention Deficit Hyperactivity Disorder, 10.3109/00048679809062715
  43. Faraone Stephen V., Biederman Joseph, Monuteaux Michael C., Toward guidelines for pedigree selection in genetic studies of attention deficit hyperactivity disorder, 10.1002/(sici)1098-2272(200001)18:1<1::aid-gepi1>;2-x
  44. Vaidya C. J., Austin G., Kirkorian G., Ridlehuber H. W., Desmond J. E., Glover G. H., Gabrieli J. D. E., Selective effects of methylphenidate in attention deficit hyperactivity disorder: A functional magnetic resonance study, 10.1073/pnas.95.24.14494
  45. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M, Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism, 10.1038/
  46. FARAONE SV, Am. j Psychiatry, 156, 768 (1999)
  47. LAHOSTE GJ, Mol. Psychiatry, 1, 121 (1996)
  48. Smalley S L, Bailey J N, Palmer C G, Cantwell D P, McGough J J, Del'Homme M A, Asarnow J R, Woodward J A, Ramsey C, Nelson S F, Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder, 10.1038/
  49. Rowe D C, Stever C, Giedinghagen L N, Gard J M C, Cleveland H H, Terris S T, Mohr J H, Sherman S, Abramowitz A, Waldman I D, Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder, 10.1038/
  50. Caine S Barak, Koob George F., Parsons Loren H., Everitt Barry J., Schwartz Jean-Charles, Sokoloff Pierre, D3 receptor test in vitro predicts decreased cocaine self-administration in rats : , 10.1097/00001756-199707070-00054
  51. Nader M. A., Mach R. H., Self-administration of the dopamine D3 agonist 7-OH-DPAT in rhesus monkeys is modified by prior cocaine exposure, 10.1007/bf02247388
  52. Lamas X., Negus S. S., Mello N. K., Nader M. A., Effects of the putative dopamine D3 receptor agonist 7-OH-DPAT in rhesus monkeys trained to discriminate cocaine from saline, 10.1007/bf02247435
  53. SPEALMAN RD, j Pharmacol. Exp. Ther., 278, 1128 (1996)
  54. BAXTER LR, j Chu. Psychiatry, 49, 23 (1988)
  55. CHILDRESS AR, Soc. Neurosci Abstr., 20, 1632 (1994)
  56. Grant S., London E. D., Newlin D. B., Villemagne V. L., Liu X., Contoreggi C., Phillips R. L., Kimes A. S., Margolin A., Activation of memory circuits during cue-elicited cocaine craving., 10.1073/pnas.93.21.12040
  57. WISE RA, Curl: Opin. Neurobiol, 6, 243 (1996)
  58. ROBERTS DCS, RANALDI R, Chu. Neuropharmacol, 18, S84–S95 (1995)
  59. Everitt Barry J., Sokoloff Pierre, Pilla Maria, Perachon Sylvie, Sautel FranÇois, Garrido Fabrice, Mann André, Wermuth Camille G., Schwartz Jean-Charles, 10.1038/22560
  60. Whitelaw Rachel B., Markou Athina, Robbins Trevor W., Everitt Barry J., Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaine-seeking behaviour under a second-order schedule of reinforcement, 10.1007/bf02805996
  61. HITCHCOTT PK, II. Instrumental conditioning. Psychopharmacology, 140, 310 (1998)
  62. Weiss Friedbert, Markou Athina, Lorang Marge T., Koob George F., Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration, 10.1016/0006-8993(92)91327-b
  63. Wood Martyn D, Boyfield Izzy, Nash David J, Jewitt Frances R, Avenell Kim Y, Riley Graham J, Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor, 10.1016/s0014-2999(00)00732-9
  64. ROSEN RC, j Gender-Specific Med., 3, 45 (2000)
  65. MAJ J, Polish I Pharmacol, 51, 471 (1999)
  66. SPORN J, Annals of Chu. Psychiatry, 12, 137 (2000)
  67. WAGNER ML, Sleep, 19, 52 (1996)
  68. SVENSSON K, Psychopharmacology, 37, 1037 (1993)
  69. Riffee William H., Wilcox Richard E., Effects of multiple pretreatment with apomorphine and amphetamine on amphetamine-induced locomotor activity and its inhibition by apomorphine, 10.1007/bf00427330
  70. Meil William M, See Ronald E, Lesions of the basolateral amygdala abolish the ability of drug associated cues to reinstate responding during withdrawal from self-administered cocaine, 10.1016/s0166-4328(96)02270-x
  71. De Boer P., Enrico P., Wright J., Wise L.D., Timmerman W., Moor E., Dijkstra D., Wikström H.V., Westerink B.H.C., Characterization of the effect of dopamine D3 receptor stimulation on locomotion and striatal dopamine levels, 10.1016/s0006-8993(96)01438-2
  72. Ouagazzal Abdel-Mouttalib, Creese Ian, Intra-accumbens infusion of D3 receptor agonists reduces spontaneous and dopamine-induced locomotion, 10.1016/s0091-3057(00)00406-8
  73. BARTOSZYK GD, Involvement of dopamine autoreceptors. Life Sci., 62, 649 (1998)
  74. Gendreau Paul L, Petitto John M, Petrova Andreana, Gariépy Jean-Louis, Lewis Mark H, D3 and D2 dopamine receptor agonists differentially modulate isolation-induced social-emotional reactivity in mice, 10.1016/s0166-4328(00)00193-5
  75. MONTPLAISIR J, Neurology, 52, 938 (1999)
  76. ROSENBAUM JF, Am.j Psychiatry, 156, 11)1834 (1999)
  77. Contin Manuela, Riva Roberto, Albani Fiorenzo, Baruzzi Agostino, Pharmacokinetic Optimisation of Dopamine Receptor Agonist Therapy for Parkinson??s Disease : , 10.2165/00023210-200014060-00003
  78. Corbin A.E, Meltzer L.T, Ninteman F.W, Wiley J.N, Christoffersen C.L, Wustrow D.J, Wise L.D, Pugsley T.A, Heffner T.G, PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT1A agonist actions. II. Preclinical behavioral effects, 10.1016/s0028-3908(99)00214-2